首页> 外文期刊>Immunological reviews. >Severe combined immunodeficiency. A model disease for molecular immunology and therapy.
【24h】

Severe combined immunodeficiency. A model disease for molecular immunology and therapy.

机译:严重的联合免疫缺陷。用于分子免疫学和治疗的模型疾病。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Severe combined immunodeficiencies (SCIDs) consist of genetically determined arrest of T-cell differentiation. Ten different molecular defects have now been identified, which all lead to early death in the absence of therapy. Transplantation of allogeneic hematopoietic stem cells (HSCT) can restore T-cell development, thus saving the lives of SCID patients. In this review, the different characteristics of HSCT are discussed along with the available data regarding the long-term outcome. Transient thymopoiesis caused by an exhaustion of donor progenitor cells and possibly a progressive loss of thymus function can lead to a progressive decline in T-cell functions. The preliminary results of gene therapy show the correction of two SCID conditions. Based on the assumption that long-lasting pluripotent progenitor cells are transduced, these data suggest that gene therapy could overcome the long-term recurrence of the T-cell immunodeficiency. SCID is thus a disease model for experimental therapy in the hematopoietic system.
机译:严重的联合免疫缺陷症(SCID)由基因确定的T细胞分化抑制作用组成。现在已经鉴定出十种不同的分子缺陷,如果没有治疗,它们都会导致早期死亡。同种异体造血干细胞(HSCT)的移植可以恢复T细胞发育,从而挽救SCID患者的生命。在这篇综述中,讨论了HSCT的不同特征以及有关长期结果的可用数据。由供体祖细胞的衰竭引起的短暂性胸腺生成和可能的胸腺功能逐渐丧失可能导致T细胞功能逐渐下降。基因治疗的初步结果显示了两种SCID病状的纠正。基于转导长效多能祖细胞的假设,这些数据表明基因治疗可以克服T细胞免疫缺陷的长期复发。因此,SCID是用于造血系统中实验治疗的疾病模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号